IL182507A0 - Methods of treating cancer with liqid-based platinum compound formulations administered intraperitoneally - Google Patents

Methods of treating cancer with liqid-based platinum compound formulations administered intraperitoneally

Info

Publication number
IL182507A0
IL182507A0 IL182507A IL18250707A IL182507A0 IL 182507 A0 IL182507 A0 IL 182507A0 IL 182507 A IL182507 A IL 182507A IL 18250707 A IL18250707 A IL 18250707A IL 182507 A0 IL182507 A0 IL 182507A0
Authority
IL
Israel
Prior art keywords
liqid
methods
treating cancer
administered intraperitoneally
platinum compound
Prior art date
Application number
IL182507A
Other languages
English (en)
Original Assignee
Transave Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transave Inc filed Critical Transave Inc
Publication of IL182507A0 publication Critical patent/IL182507A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL182507A 2004-11-08 2007-04-12 Methods of treating cancer with liqid-based platinum compound formulations administered intraperitoneally IL182507A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62602904P 2004-11-08 2004-11-08
US67159305P 2005-04-15 2005-04-15
PCT/US2005/040489 WO2006055352A2 (en) 2004-11-08 2005-11-08 Methods of treating cancer with lipid-based platinum compound formulations administered intraperitoneally

Publications (1)

Publication Number Publication Date
IL182507A0 true IL182507A0 (en) 2007-09-20

Family

ID=36407625

Family Applications (1)

Application Number Title Priority Date Filing Date
IL182507A IL182507A0 (en) 2004-11-08 2007-04-12 Methods of treating cancer with liqid-based platinum compound formulations administered intraperitoneally

Country Status (9)

Country Link
US (1) US20060246124A1 (https=)
EP (1) EP1811963A4 (https=)
JP (2) JP5735724B2 (https=)
KR (1) KR20070089693A (https=)
AU (1) AU2005306802A1 (https=)
CA (1) CA2584673A1 (https=)
IL (1) IL182507A0 (https=)
MX (1) MX2007004955A (https=)
WO (1) WO2006055352A2 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ2004964A3 (cs) * 2004-09-14 2006-03-15 Pliva-Lachema A. S. Perorální farmaceutická kompozice pro cílený transport komplexu platiny do kolorektální oblasti, zpusob její prípravy a tato kompozice pro pouzití jako lécivo
US9107824B2 (en) 2005-11-08 2015-08-18 Insmed Incorporated Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
US7875288B2 (en) * 2006-03-30 2011-01-25 The Research Foundation Of State University Of New York Method for treating blood coagulation disorders
WO2007117469A2 (en) * 2006-03-30 2007-10-18 The Research Foundation Of State University Of New York Compositions of less immunogenic and long-circulating protein-lipid complexes
CZ300590B6 (cs) * 2006-06-20 2009-06-24 Pliva - Lachema A. S. Farmaceutická kompozice pro injekcní podání
CZ300424B6 (cs) * 2006-06-20 2009-05-13 Pliva - Lachema A. S. Farmaceutická kompozice pro perorální podání
US8168661B2 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8178564B2 (en) * 2006-11-06 2012-05-15 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168662B1 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8173686B2 (en) 2006-11-06 2012-05-08 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US9814672B2 (en) * 2007-03-09 2017-11-14 Susan T. Laing Echogenic vehicle for clinical delivery of plasminogen activator and other fibrin-binding therapeutics to thrombi
KR101085203B1 (ko) 2011-04-01 2011-11-21 서울대학교산학협력단 의약 전달용 인지질 나노입자
DK2892524T3 (da) 2012-09-04 2021-01-25 Eleison Pharmaceuticals LLC Forebyggelse af pulmonalt kræfttilbagefald med lipid-komplekseret cisplatin
AU2019372441A1 (en) * 2018-11-02 2021-06-10 Tesorx Pharma, Llc Liposomal enhanced intra-peritoneal chemotherapy
CA3243794A1 (en) * 2022-02-07 2023-08-10 Livful Inc PREPARATION OF NEW TRITERPENE ALCOHOL DERIVATIVES WITH IMPROVED BIOAVAILABILITY FOR THE TREATMENT OF CANCER, INFLAMMATION AND PAIN
CN118059258B (zh) * 2024-03-07 2024-11-15 内蒙古工业大学 一种治疗口腔鳞状细胞癌顺铂耐药的纳米药物及其制备方法和应用

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4451447A (en) * 1980-03-31 1984-05-29 Bristol-Myers Company Pharmaceutical formulations
US4981692A (en) * 1983-03-24 1991-01-01 The Liposome Company, Inc. Therapeutic treatment by intramammary infusion
USRE33071E (en) * 1983-03-28 1989-09-26 Platinum bound to transferrin for use in the treatment of breast tumors
US4590001A (en) * 1983-03-28 1986-05-20 Stjernholm Rune L Platinum bound to transferrin for use in the treatment of breast tumors
US5019369A (en) * 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
JPH0665648B2 (ja) * 1985-09-25 1994-08-24 塩野義製薬株式会社 白金系抗癌物質の安定な凍結真空乾燥製剤
US5041581A (en) * 1985-10-18 1991-08-20 The University Of Texas System Board Of Regents Hydrophobic cis-platinum complexes efficiently incorporated into liposomes
US5117022A (en) * 1985-10-18 1992-05-26 The Board Of Regents, The University Of Texas System Hydrophobic cis-platinum complexes efficiently incorporated into liposomes
US5049388A (en) * 1986-11-06 1991-09-17 Research Development Foundation Small particle aerosol liposome and liposome-drug combinations for medical use
US5320906A (en) * 1986-12-15 1994-06-14 Vestar, Inc. Delivery vehicles with amphiphile-associated active ingredient
MX9203808A (es) * 1987-03-05 1992-07-01 Liposome Co Inc Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos.
US5616334A (en) * 1987-03-05 1997-04-01 The Liposome Company, Inc. Low toxicity drug-lipid systems
IL83380A (en) * 1987-07-30 1991-04-15 Teva Pharma Stable aqueous cisplatin solutions
DE68901733T2 (de) * 1988-03-04 1993-03-25 Takeda Chemical Industries Ltd Liposom-zusammensetzung.
US5141751A (en) * 1988-06-29 1992-08-25 Daiichi Pharmaceutical Co., Ltd. Lipid membrane structures
US5549910A (en) * 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
US5225212A (en) * 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5747469A (en) * 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
JP3220180B2 (ja) * 1991-05-23 2001-10-22 三菱化学株式会社 薬剤含有タンパク質結合リポソーム
US5756353A (en) * 1991-12-17 1998-05-26 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol-and liposome-based delivery
US5858784A (en) * 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5958449A (en) * 1992-12-02 1999-09-28 Nexstar Pharmaceuticals, Inc. Antibiotic formulation and use for bacterial infections
US5665383A (en) * 1993-02-22 1997-09-09 Vivorx Pharmaceuticals, Inc. Methods for the preparation of immunostimulating agents for in vivo delivery
US5780054A (en) * 1996-01-17 1998-07-14 University Of British Columbia Methods for increasing the circulation half-life of protein-based therapeutics
EP0896816A4 (en) * 1996-02-26 2002-06-12 Daiichi Seiyaku Co LIPOSOME AND LIPOSOME DISPERSION
PT910382E (pt) * 1996-04-26 2003-10-31 Genaera Corp Esqualamina em combinacao com outros agentes anti-cancro para o tratamento de tumores
ATE252372T1 (de) * 1996-08-23 2003-11-15 Sequus Pharm Inc Liposome enthaltend cisplatin
US5997899A (en) * 1996-10-01 1999-12-07 Skyepharma Inc. Method for producing liposomes with increased percent of compound encapsulated
US6451784B1 (en) * 1996-12-30 2002-09-17 Battellepharma, Inc. Formulation and method for treating neoplasms by inhalation
AU741439B2 (en) * 1996-12-30 2001-11-29 Battelle Memorial Institute Formulation and method for treating neoplasms by inhalation
US6630168B1 (en) * 1997-02-20 2003-10-07 Biomedicines, Inc. Gel delivery vehicles for anticellular proliferative agents
US6090407A (en) * 1997-09-23 2000-07-18 Research Development Foundation Small particle liposome aerosols for delivery of anti-cancer drugs
US6787132B1 (en) * 1997-12-04 2004-09-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Combined chemo-immunotherapy with liposomal drugs and cytokines
US6726925B1 (en) * 1998-06-18 2004-04-27 Duke University Temperature-sensitive liposomal formulation
CA2248592A1 (en) * 1998-08-31 2000-02-29 Christopher D. Batich Microspheres for use in the treatment of cancer
ES2156506B1 (es) * 1998-10-14 2002-03-01 Sumitomo Chemical Co Metodo para la produccion de oxido de propileno.
US20050074499A1 (en) * 1999-03-17 2005-04-07 Mitsubishi Chemical Corporation Ligand-bonded complex
US6723338B1 (en) * 1999-04-01 2004-04-20 Inex Pharmaceuticals Corporation Compositions and methods for treating lymphoma
US6852334B1 (en) * 1999-04-20 2005-02-08 The University Of British Columbia Cationic peg-lipids and methods of use
WO2000074634A2 (en) * 1999-06-03 2000-12-14 Au Jessie L S Methods and compositions for modulating cell proliferation and cell death
US6352996B1 (en) * 1999-08-03 2002-03-05 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
US6800437B1 (en) * 1999-08-06 2004-10-05 Tibotec Bvba Method of monitoring a biological system by labeling with an apo metal binding protein
US6511676B1 (en) * 1999-11-05 2003-01-28 Teni Boulikas Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes
EP1242106A4 (en) * 1999-12-04 2008-08-27 Res Dev Foundation IMPROVING INHALATION THERAPY USING CARBON GAS
DE60123583T2 (de) * 2000-02-04 2007-08-09 Lipoxen Technologies Ltd. Dehydratisierungs-/rehydratisierungsverfahren zur herstellung von liposome
WO2001082892A2 (de) * 2000-05-02 2001-11-08 Pharmacept Gmbh Wirkstoffhaltige liposome
JP2004501955A (ja) * 2000-06-30 2004-01-22 アイネックス　ファーマシューティカルズ　コーポレイション リポソーム抗新生物薬剤およびその使用
WO2002060412A2 (en) * 2001-02-01 2002-08-08 Board Of Regents Stabilised polymeric aerosols for pulmonary gene delivery
JP2004529929A (ja) * 2001-04-23 2004-09-30 ニュクリスト ファーマシューティカルズ コーポレーション アポトーシスの誘導およびマトリックスメタロプロテイナーゼの阻害のための金属の使用
US20030143162A1 (en) * 2001-05-18 2003-07-31 Speirs Robert John Methods and unit dose formulations for the inhalation administration of aminoglycoside antibiotics
AU2002323151A1 (en) * 2001-08-13 2003-03-03 University Of Pittsburgh Application of lipid vehicles and use for drug delivery
CA2456746A1 (en) * 2001-08-20 2003-02-27 Transave, Inc. Method for treating lung cancers
US6793912B2 (en) * 2001-08-20 2004-09-21 Transave Inc. Treatment of cancers by inhalation of stable platinum-containing formulations
US20040022842A1 (en) * 2002-06-03 2004-02-05 Mebiopharm Co., Ltd. Liposome preparations containing oxaliplatin
JP3415131B1 (ja) * 2002-06-03 2003-06-09 メビオファーム株式会社 リポソーム製剤
EP1545459A4 (en) * 2002-08-02 2007-08-22 Transave Inc PLATINUM AGGREGATES, AND METHOD FOR MANUFACTURING THE SAME
AU2003298738A1 (en) * 2002-11-26 2004-06-18 Su-Ming Chiang Liposomal formulations

Also Published As

Publication number Publication date
CA2584673A1 (en) 2006-05-26
JP2015098498A (ja) 2015-05-28
AU2005306802A1 (en) 2006-05-26
WO2006055352A3 (en) 2006-07-27
EP1811963A4 (en) 2010-01-06
JP2008519064A (ja) 2008-06-05
JP5735724B2 (ja) 2015-06-17
US20060246124A1 (en) 2006-11-02
WO2006055352A2 (en) 2006-05-26
MX2007004955A (es) 2007-06-14
EP1811963A2 (en) 2007-08-01
KR20070089693A (ko) 2007-08-31

Similar Documents

Publication Publication Date Title
IL182507A0 (en) Methods of treating cancer with liqid-based platinum compound formulations administered intraperitoneally
PL1765391T3 (pl) Kompozycje bakteryjne do leczenia nowotworów
IL227841A0 (en) Dihydropyridinones for the treatment of cancer
IL188746A0 (en) Treatment of cancer
IL180729A0 (en) Compounds and methods for treatment of cancer
IL188430A0 (en) Treatment of tumors
IL179401A0 (en) Therapy of platinum-resistant cancer
EP1830847A4 (en) ANTICANCER TREATMENT
IL179129A0 (en) Kit for treatment of cancer
GB0428187D0 (en) Cancer treatment
PL1803456T3 (pl) Kompozycje farmaceutyczne zawierające L-733060 do zastosowania w leczeniu guzów nowotworowych
IL177455A0 (en) Pyrazoline derivatives useful for the treatment of cancer
EP1789064A4 (en) ENHANCED ANTICANCER TREATMENT
ZA200704150B (en) Methods of treating cancer with lipid-based platinum compound formulations administered intraperitoneally
IL175689A0 (en) Enoxaparin for the treatment of cancer
GB0329416D0 (en) Treatment of cancer
IL180709A0 (en) Treatment of tumours
GB0520067D0 (en) Treatment of cancer
GB0410379D0 (en) Treatment of cancer
GB0423273D0 (en) Treatment of cancer
GB0404675D0 (en) Cancer treatment
GB0421734D0 (en) Treatment of cancer
GB0422225D0 (en) Treatment of cancer
GB0420845D0 (en) Treatment of cancer
ZA200700845B (en) Treatment of cancer